1st Patients Dosed with Newly Approved Brain Cancer Imaging Agent

Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan (NASDAQ:TLX)

Telix Pharmaceuticals advances its imaging and therapeutic portfolio, highlighted by Pixclara's FDA approval & rapid commercial rollout. Read more on TLX stock.

1st patients dosed with newly approved brain cancer imaging agent

Indiana University Health says it is the first hospital system in the U.S. to administer Pixclara, a pharmaceutical used to help radiologists evaluate suspected recurrent disease.

Telix Pharmaceuticals reports first US Pixclara doses

Telix said on Oct. 6 that first U.S. patients had received Pixclara in Cleveland and Indianapolis; its launch release set no sales target.

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) - Telix Pharmaceuticals Limited

Telix today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.